Skip to main content
Fig. 4 | Journal of Nanobiotechnology

Fig. 4

From: A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease

Fig. 4

The biophysical stability evaluation of C44-Fc in vitro. a SEC-HPLC profile of C44-Fc and evinacumab. b Time course analysis of C44-Fc expression levels in ExpiCHO cells. The culture supernatants of ExpiCHO cells transiently transfected with C44-Fc, evinacumab and control Ab expression plasmid were collected on days 5–12. c and d SEC-HPLC analysis of C44-Fc and evinacumab at low or high pH. C44-Fc and evinacumab were preserved at pH 5.0 or pH 9.0 and 40 ℃ for 72 h. e SEC-HPLC analysis of C44-Fc and evinacumab at 40 ℃ for 28 days. f The freeze–thaw stability analysis of C44-Fc and evinacumab by SEC-HPLC

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us